Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dmitriy Zak (NPI 1548371289)

Field	Value
Entity Type	Individual
Organization	Dmitriy Zak
Address	639 Hospital Dr
City	Mountain Home
State	AR
ZIP	72653
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 31, 2006

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

DMITRIY ZAK is a Hematology & Oncology Physician based in MOUNTAIN HOME, AR with an NPI enumerated 2006-08-31 (~20 years ago). The provider reports total Medicare revenue of $2.2M and has no Medicaid billing on file, making the practice effectively single‑payer (Medicare) in scale and exposure.

Revenue is highly concentrated in a small set of infused oncology agents: the precomputed top three Medicare codes account for 73.9% of this provider's total Medicare revenue, with J9271 alone representing 43.3% and J9144 contributing 22.0% of Medicare revenue as reported. This concentration indicates that a large share of the practice’s income is driven by a few high-cost drug administrations rather than by diverse ancillary services.

The CPT/HCPCS mix (notably J9271, J9144, J0897, plus administration codes such as 96413 and 96417) describes an outpatient infusion/oncology service line focused on systemic cancer therapies and supportive agents. Presence of drug codes for pembrolizumab, daratumumab and denosumab together with chemotherapy administration add‑ons suggests the practice operates an infusion suite delivering immunotherapy/monoclonal antibody treatments and bone‑modifying agents.

Competitive standing for the top drug codes is generally modest rather than dominant: J9271 ranks #346 of 1841 providers nationally (81th percentile; typical, unremarkable volume), J9144 ranks #147 of 615 providers nationally (75th percentile; typical, unremarkable volume), and J0897 ranks #1243 of 10057 providers nationally (88th percentile; typical, unremarkable volume). Those ranks indicate the provider is a routine-volume participant for these high-revenue oncology drugs at a national level, not an outlier leader.

Clinical E/M activity is unusually high relative to peers: 99214 is labeled an "extreme outlier" (rank #2653 of 479517 providers nationally, 99th percentile; extreme outlier, far above typical national volume). This suggests heavier-than-typical office follow-up or management visits for established patients in addition to infusion throughput, indicating a substantial outpatient management workload.

In-office diagnostic and lab testing volumes appear elevated for certain panels: 80053 (CMP) ranks #1620 of 26416 (94th percentile; typical, unremarkable volume), 85025 (CBC) ranks #2393 of 32833 (93th percentile; typical, unremarkable volume), and 83735 (magnesium) ranks #458 of 6938 (93th percentile; typical, unremarkable volume). These high percentiles for lab CPTs are consistent with frequent monitoring of oncology patients receiving systemic therapies.

The practice shows use of biosimilars and supportive biologics at modest scale: Q5115 (rituximab‑abbs, truxima) accounts for 5.2% of Medicare revenue and ranks #21 of 79 providers nationally (74th percentile; typical, unremarkable volume), while Q5108 (pegfilgrastim‑jdmb) appears among peers at rank #33 of 125 (74th percentile; typical, unremarkable volume). This pattern indicates adoption of biosimilar products alongside branded monoclonal therapies, but within a relatively small national cohort of billers for some biosimilars.

Payer mix and business risk considerations: with $2.2M in Medicare revenue and "none" for Medicaid on file, this provider is effectively reliant on Medicare as the sole reported public payer, concentrating reimbursement risk and limiting exposure to Medicaid populations. Strategic or operational planning by payers or competitors should account for that single‑payer concentration alongside the heavy reliance on a few high‑revenue oncology drug codes (top three = 73.9%).

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

83 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,000	$40	$903K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	12,060	$40	$458.3K
J0897	Injection, denosumab, 1 mg	9,540	$20	$181.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,660	$80	$139.4K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	3,370	$30	$107.9K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	9,300	$10	$93K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	440	$90	$40.4K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	480	$80	$40.4K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	1,890	$10	$11.3K
99232	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or…	190	$60	$11K

Showing 1–10 of 83

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 83 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Dmitriy Zak — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

83 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	19	40	20,700	$40	$896.3K
J9144	4	10	10,530	$40	$361.9K
J9264	6	10	9,300	$10	$96.2K
Q5115	6	20	2,800	$30	$95.9K
J0897	25	160	2,580	$20	$89.7K
J0885	35	40	4,070	$10	$38K
96413	37	80	380	$90	$36.6K
Q5108	2	10	260	$90	$28.1K
93306	214	240	270	$60	$21.2K
99214	39	4,300	130	$70	$18.8K

Showing 1–10 of 83

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dmitriy Zak, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Baxter County Regional Hospital, Inc	AR	General Acute Care Hospital	$0	$15.2M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Baxter County Regional Hospital Inc	AR	General Acute Care Hospital	$0	$3M
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Dmitriy Zak, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Gracon, Inc.	AR	Home Health Agency	$0	$23.1M
Kidspiration Pediatric Therapy Services, Inc.	AR	Primary Care Clinic/Center	$0	$16.5M
Developmental Discoveries, Inc.	AR	In Home Supportive Care Agency	$0	$8M
River Lodge Assisted Living LLC	AR	Assisted Living Facility	$0	$5.1M
Bradley Wayne Coleman,d.d.s.	AR	Dentist	$0	$3.6M
Hometown Behavioral Health Services Of Ak Inc.	AR	Mental Health Counselor	$0	$3.5M
Baxter Day Service Center, Inc.	AR	Preferred Provider Organization	$0	$3.4M
Twin River Community Living Facility	AR	In Home Supportive Care Agency	$0	$2.5M
Richard White	AR	Hematology & Oncology Physician	$2.2M	$0
Interventional Pain Management Associates PLLC	AR	Interventional Pain Medicine Physician	$0	$2.1M

Dmitriy Zak — Billing Profile & Reimbursement Data

Sign up for Dmitriy Zak — Billing Profile & Reimbursement Data policy alerts

Dmitriy Zak — Billing Profile & Reimbursement Data

Sign up for Dmitriy Zak — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References